NewsDialy
A reverse merger, where a private startup absorbs a listed company to inherit its exchange slot rather than run a traditional initial public offering, is how Slate Medicines is entering the public markets.
The migraine drug startup, which launched earlier this year, announced Monday it will combine with Fulcrum Therapeutics, a biotech that shut its lead drug program two months ago.
The combined company will trade on Nasdaq under the ticker symbol SLTE.
How Fulcrum got here Fulcrum spent years on pociredir, a sickle cell drug designed to raise fetal hemoglobin levels by blocking a cluster of proteins called PRC2.
Keep reading